← Azimuth Daily
Capturing data…
Capturing data…
MON, 28 SEPT · 76 ITEMS
"Anticoagulants cut serious events by 69% in intermediate-risk atrial fibrillation patients in SINGLE-AF trial" — Science Daily (all) · Science & Medicine
The is a randomized study showing that direct oral (DOACs) — commonly known as blood thinners — reduce the risk of serious events such as stroke, systemic embolism, and death by 69% in patients with who are at of stroke. This fills a gap in evidence because guidelines have been clear for high-risk patients but uncertain for those with intermediate risk, often defined by a CHA2DS2-VASc score of 1 in men or 2 in women.
The claim is solidly grounded in a named, peer-reviewed clinical trial (SINGLE-AF) presented at the European Society of Cardiology Congress 2026. Multiple reputable science, medical, and news outlets (Science Daily, Medscape, Medical Xpress, SciTechDaily) reported consistent numbers and framing, all pointing back to the same trial data presented in Munich. Without seeing the full trial publication, the secondary reporting is consistent and authoritative.
Genuinely new: the reporting was published on September 27, 2026, based on trial results presented in late August 2026 at a major cardiology conference.